Elliot Wilbur
Stock Analyst at Raymond James
(0.55)
# 2,294
Out of 4,479 analysts
43
Total ratings
21.43%
Success rate
-19.38%
Average return
Main Sectors:
13 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADMA ADMA Biologics | Maintains: Strong Buy | $8 → $10 | $11.55 | -13.42% | 5 | May 10, 2024 | |
| SLGL Sol-Gel Technologies | Maintains: Strong Buy | $9 → $7 | $0.86 | +713.95% | 7 | Aug 11, 2023 | |
| ANIP ANI Pharmaceuticals | Maintains: Outperform | $48 → $49 | $63.44 | -22.76% | 5 | May 9, 2023 | |
| OGN Organon & Co. | Initiates: Outperform | $33 | $20.31 | +62.48% | 1 | Mar 16, 2023 | |
| PRGO Perrigo Company | Maintains: Outperform | $42 → $43 | $26.25 | +63.81% | 5 | Mar 6, 2023 | |
| PETQ PetIQ | Maintains: Outperform | $21 → $16 | $22.87 | -30.04% | 4 | Oct 25, 2022 | |
| PYPD PolyPid | Downgrades: Outperform | $450 → $120 | $4.24 | +2,730.19% | 2 | Sep 6, 2022 | |
| VTRS Viatris | Downgrades: Market Perform | n/a | $10.59 | - | 3 | Mar 1, 2022 | |
| TEVA Teva Pharmaceutical | Downgrades: Market Perform | n/a | $16.34 | - | 2 | Oct 28, 2021 | |
| ZTS Zoetis | Downgrades: Market Perform | n/a | $172.58 | - | 4 | Jul 16, 2021 | |
| ELAN Elanco Animal Health | Initiates: Market Perform | n/a | $14.10 | - | 1 | Jan 10, 2020 | |
| DERM Journey Medical | Upgrades: Market Perform | n/a | $5.37 | - | 2 | Jan 17, 2019 | |
| AMPH Amphastar Pharmaceuticals | Downgrades: Market Perform | n/a | $38.51 | - | 2 | Nov 9, 2017 |
ADMA Biologics
May 10, 2024
Maintains: Strong Buy
Price Target: $8 → $10
Current: $11.55
Upside: -13.42%
Sol-Gel Technologies
Aug 11, 2023
Maintains: Strong Buy
Price Target: $9 → $7
Current: $0.86
Upside: +713.95%
ANI Pharmaceuticals
May 9, 2023
Maintains: Outperform
Price Target: $48 → $49
Current: $63.44
Upside: -22.76%
Organon & Co.
Mar 16, 2023
Initiates: Outperform
Price Target: $33
Current: $20.31
Upside: +62.48%
Perrigo Company
Mar 6, 2023
Maintains: Outperform
Price Target: $42 → $43
Current: $26.25
Upside: +63.81%
PetIQ
Oct 25, 2022
Maintains: Outperform
Price Target: $21 → $16
Current: $22.87
Upside: -30.04%
PolyPid
Sep 6, 2022
Downgrades: Outperform
Price Target: $450 → $120
Current: $4.24
Upside: +2,730.19%
Viatris
Mar 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $10.59
Upside: -
Teva Pharmaceutical
Oct 28, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $16.34
Upside: -
Zoetis
Jul 16, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $172.58
Upside: -
Elanco Animal Health
Jan 10, 2020
Initiates: Market Perform
Price Target: n/a
Current: $14.10
Upside: -
Journey Medical
Jan 17, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $5.37
Upside: -
Amphastar Pharmaceuticals
Nov 9, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $38.51
Upside: -